Evonik and Heraeus Precious Metals are collaborating to expand both companies’ range of services for highly potent active pharmaceutical ingredients (HPAPIs). The alliance leverages specific HPAPI capabilities of both companies to provide an integrated offering from the preclinical stage to commercial manufacturing, including streamlined transfer between small and large-scale production.
 
Evonik’s Health Care business provides CDMO services for active pharmaceutical ingredients (APIs) and intermediates. The partnership with Heraeus Precious Metals builds on the company’s experience delivering complex APIs for clinical and commercial supply needs of pharma and biopharma customers globally.
 
The Pharmaceutical Ingredients business at Heraeus Precious Metals offers customized solutions for both earlier and later clinical phases and smaller to mid-volume HPAPI commercial products in the marketplace.
 
“As one of the earliest adopters of large-scale HPAPI production, our offering is perfectly complemented by that of Heraeus. This alliance benefits clients needing to develop and launch HPAPIs safely and quickly,” said Stefan Randl, head of Evonik’s Drug Substance product line.
 
“The supplementary approach with Evonik is thus a natural fit for Heraeus Precious Metals as it allows a smooth upscaling of small- and medium-scale projects that require larger scale commercial production at a later stage,” said Marcus Hannakam, executive vice president business line Pharmaceutical Ingredients.